다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Current problems of psychiatry, v.19 no.4, 2018년, pp.285 - 298
Siembida, Jakub (Student Research Group at the I Department of Psychiatry, Psychotherapy and Early Intervention, Medical University of Lublin) , Karakuła, Kaja
AbstractIntroduction:Gamma-hydroxybutyric acid (GHB) is commonly known as a recreation drug or the so-called “date rape drug”. It is also used in medicine to treat narcolepsy and alcohol addiction. GHB has an affinity for two types of receptors: GABABand the relatively recently discovered GHB receptors. GHB receptors were first cloned in 2003 in mice and then in 2007 in humans. So far, evidence has been presented for their impact on dopaminergic transmission, which may imply that they play a role in the pathogenesis of diseases such as schizophrenia. At the same time, it has been demonstrated that benzamide antipsychotic drugs have an affinity for GHB receptors, which is why it is postulated that some of the effects of these drugs may result precisely from this affinity.Aim:The study presents the current state of knowledge about GHB receptors and their potential role in the pathogenesis of schizophrenia, and discusses drugs which show an affinity for this receptor.Material and method:The literature review was based on a search of articles indexed between 1965 and 2018 in Medline, Google Scholar, ScienceDirect and Research Gate databases. The following search terms were used: GHB receptor, GHB, sulpiride, and amisulpride.Result and discussion:1. It is possible that GHB receptors are involved in the pathogenesis of schizophrenia, although more research is needed in this area. 2. Part of the effects of some benzamide antipsychotic drugs (such as amisulpride) may be due to their affinity for GHB receptors.
10.1096/fj.06-6509com 1. Andriamampandry C, Taleb O, Kemmel V, Humbert JP, Aunis D, Maitre M. Cloning and functional characterization of a gamma-hydroxybutyrate receptor identified in the human brain. FASEB J. 2007; 21(3): 885-895.10.1096/fj.06-6509com
10.1046/j.1471-4159.2000.0751986.x 2. Snead OC 3rd. Evidence for a G protein-coupled gamma-hydroxybutyric acid receptor. J Neurochem 2000; 75(5): 1986-1996.
10.1096/fj.02-0846fje 3. Andriamampandry C, Taleb O, Viry S, Muller C, Humbert JP, Gobaille S, et al. Cloning and characterization of a rat brain receptor that binds the endogenous neuromodulator gamma-hydroxybutyrate (GHB). FASEB J. 2003; 17(12): 1691-1693.10.1096/fj.02-0846fje
10.1016/0006-8993(94)90874-5 4. Snead OC 3rd. The ontogeny of [3H]gamma-hydroxybutyrate and [3H]GABAB binding sites: relation to the development of experimental absence seizures. Brain Res. 1994; 659(1-2): 147-156.10.1016/0006-8993(94)90874-5
10.1002/cne.21072 5. Kemmel V, Miehe M, Roussel G, Taleb O, Nail-Boucherie K, Marchand C, et al. Immunohistochemical Localization of a GHB Receptor-Like Protein Isolated from Rat Brain. The Journal of Comparative Neurology 2006; 498: 508-524.10.1002/cne.21072
10.1002/med.21382 6. 6. Maitre M, Klein C, Mensah-Nyagan AG. Mechanisms for the Specific Properties of γ -Hydroxybutyrate in Brain. Medicinal Research Reviews 2016; 36(3): 363-388.10.1002/med.21382
10.1016/j.tips.2003.11.001 7. Wong CGT, Gibson KM, Snead OC 3rd. From the street to the brain: neurobiology of the recreational drug γ-hydroxybutyric acid. Trends in Pharmacological Sciences 2004; 25(1): 29-34.10.1016/j.tips.2003.11.001
10.1016/j.neuropharm.2004.08.019 8. Wu Y, Ali S, Ahmadian G, Liu CC, Wang YT, Gibson KM, et al. Gamma-hydroxybutyric acid (GHB) and gamma-aminobutyric acidB receptor (GABABR) binding sites are distinctive from one another: molecular evidence. Neuropharmacology 2004; 47(8): 1146-1156.10.1016/j.neuropharm.2004.08.019
10.1051/medsci/2005213284 9. Maitre M, Humbert JP, Kemmel V, Aunis D, Andriamampandry C. A mechanism for gamma-hydroxybutyrate (GHB) as a drug and a substance of abuse. Med Sci (Paris) 2005; 21(3): 284-289.10.1051/medsci/2005213284
10.1016/S0006-2952(99)00265-8 10. Cash CD, Gobaille S, Kemmel V, Andriamampandry C, Maitre M. Gamma-hydroxybutyrate receptor function studied by the modulation of nitric oxide synthase activity in rat frontal cortex punches. Biochem Pharmacol. 1999; 58(11): 1815-1819.10.1016/S0006-2952(99)00265-8
10.1111/j.1471-4159.1991.tb02012.x 11. Hechler V, Gobaille S, Bourguignon JJ, Maitre M. Extracellular events induced by gamma-hydroxybutyrate in striatum: a microdialysis study. J Neurochem. 1991; 56(3): 938-944.10.1111/j.1471-4159.1991.tb02012.x1847191
12. Maitre M, Hechler V, Vayer P, Gobaille S, Cash CD, Schmitt M, et al. A specific gamma-hydroxybutyrate receptor ligand possesses both antagonistic and anticonvulsant properties. J Pharmacol Exp Ther. 1990; 255(2): 657-663.
10.1016/0014-2999(95)00369-V 13. Smolders I, De Klippel N, Sarre S, Ebinger G, Michotte Y. Tonic GABA-ergic modulation of striatal dopamine release studied by in vivo microdialysis in the freely moving rat. Eur J Pharmacol. 1995; 284(1-2): 83-91.10.1016/0014-2999(95)00369-V
10.1016/S0893-133X(99)00066-4 14. Schmidt-Mutter C, Muller C, Zwiller J, Gobaille S, Maitre M. Gamma-Hydroxybutyrate and Cocaine Administration Increases mRNA Expression of Dopamine D1 and D2 Receptors in Rat Brain. Neuropharmacology 1999; 21(5): 662-669.
10.1046/j.1471-4159.2003.02037.x 15. Castelli MP, Ferraro L, Mocci I, Carta F, Carai MAM, Antonelli T, et al. Selective c-hydroxybutyric acid receptor ligands increase extracellular glutamate in the hippocampus, but fail to activate G protein and to produce the sedative/hypnotic effect of c-hydroxybutyric acid. Journal of Neurochemistry 2003; 87(3): 722-723.10.1046/j.1471-4159.2003.02037.x
10.1016/j.pbb.2004.09.022 16. Sircara R, Basaka A. Adolescent g-hydroxybutyric acid exposure decreases cortical N-methyl-d-aspartate receptor and impairs spatial learning. Pharmacology, Biochemistry and Behavior 2004; 79(4): 701-708.10.1016/j.pbb.2004.09.022
10.1046/j.1471-4159.2001.00530.x 17. Ferraro L, Tanganelli S, O’Connor WT, Francesconi W, Loche A, Gessa GL, et al. γ-Hydroxybutyrate modulation of glutamate levels in the hippocampus: an in vivo and in vitro study. Journal of Neurochemistry 2001; 78(5): 929-939.10.1046/j.1471-4159.2001.00530.x
10.1016/S0024-3205(01)01526-0 18. Gobaille S, Schleef C, Hechler V, Viry S, Aunis D, Maitre M. Gamma-hydroxybutyrate increases tryptophan availability and potentiates serotonin turnover in rat brain. Life Sciences 2002; 70(18): 2101-2112.10.1016/S0024-3205(01)01526-0
10.1016/S0031-6989(73)80025-6 19. Spano PF, Przegalinski E. Stimulation of serotonin synthesis by anesthetic and non-anesthetic doses of gamma-hydroxybutyrate. Pharmacological Research Communications 1973; 5(1): 55-69.10.1016/S0031-6989(73)80025-6
10.1007/BF01250046 20. Hedner Th, Lundborg P. Effect of gammahydroxybutyric acid on serotonin synthesis, concentration and metabolism in the developing rat brain. Journal of Neural Transmission 1983; 57(1-2): 39-48.10.1007/BF012500466194255
21. Stahl SM. Podstawy psychofarmakologii. Teoria i praktyka. T. 2. Gdańsk: Via Medica, 2009, s. 20-55. ISBN 978-83-7599-070-6.
10.1177/026988110101500108 22. Bantick RA, Deakin JFW, Grasby PM. The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?. Journal of Psychopharmacology 2001; 15(1): 37-46.10.1177/02698811010150010811277607
10.1007/BF00973292 23. Miguez I, Aldegunde M, Duran R, Veira JAR. Effect of Low Doses of Gamma-Hydroxybutyric Acid on Serotonin, Noradrenaline, and Dopamine Concentrations in Rat Brain Areas. Neurochemical Research 1988; 13(6): 531-533.10.1007/BF009732922457177
10.1016/j.ghir.2004.03.006 24. Cauter E, Latta F, Nedeltcheva A, Spiegel K, Leproult R, Vandenbril C, et al. Reciprocal interactions between the GH axis and sleep. Growth Hormone & IGF Research 2004; 14: 10-17.10.1016/j.ghir.2004.03.00615135771
10.1210/jcem-44-5-1014 25. Takahara J, Yunoki S, Yakushiji W, Yamauchi J, Yamane Y, Ofuji, T. Stimulatory effects of gamma-hydroxybutyric acid on growth hormone and prolactin release in humans. J. Clin. Endocrinol. Metab. 1977; 44: 1014-1017.
10.1172/JCI119587 26. van Cauter E, Plat L, Scharf MB, Leproult R, Cespedes S, L’Hermite-Balériaux M, et al. Simultaneous Stimulation of Slow-wave Sleep and Growth Hormone Secretion by Gamma-hydroxybutyrate in Normal Young Men. The Journal of clinical investigation, 1997; 100(3): 745-753.10.1172/JCI119587
10.1016/S0741-8329(99)00094-4 27. Rigamonti AE, Müller EE. Gamma-hydroxybutyric acid and growth hormone secretion Studies in rats and dogs. Alcohol 2000; 20(3): 293-304.10.1016/S0741-8329(99)00094-4
10.1159/000126152 28. Cocilovo L, de Gennaro Colonna V, Zoli M, Biagini G, Settembrini BP, Müller EE, et al. Central Mechanisms Subserving the Impaired Growth Hormone Secretion Induced by Persistent Blockade of NM DA Receptors in Immature Male Rats. Neuroendocrinology 1992; 55(4): 416-421.10.1159/000126152
10.1007/s007260050001 29. Tena-Sempere M, Pinilla L, González LC, Aguilar E. Tena-Sempere, M., Pinilla, L., et al. Regulation of Growth Hormone (GH) secretion by different glutamate receptor subtypes in the rat. Amino Acids 2000; 18(1): 1-16.10.1007/s007260050001
10.1385/ENDO:28:3:295 30. Aguilar E, Tena-Sempere M, Pinilla L. Role of Excitatory Amino Acids in the Control of Growth Hormone Secretion. Endocrine 2005; 28(3): 295-302.10.1385/ENDO:28:3:295
10.1093/jat/bkw107 31. Brailsford AD, Bartlett C, Kicman AT, Cowan DA. Increases in Serum Growth Hormone Concentrations Associated with GHB Administration. Journal of Analytical Toxicology 2016; 41(1): 54-59.10.1093/jat/bkw107
10.3109/15563650.2012.702218 32. Schep LJ, Knudsen K, Slaughter RJ, Vale JA, Mégarbane B. The clinical toxicology of γ-hydroxybutyrate, γ-butyrolactone and 1,4-butanediol. Clin Toxicol (Phila) 2012; 60(6): 458-470.10.3109/15563650.2012.702218
10.1016/S0741-8329(99)00090-7 33. Galloway GP, Frederick-Osborne SL, Seymour R, Contini SE, Smith DE. Abuse and therapeutic potential of gamma-hydroxybutyric acid. Alcohol. 2000; 20(3): 263-269.10.1016/S0741-8329(99)00090-7
10.2174/1570159X13666141210215423 34. Busardò FP, Jones AW. GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome. Curr Neuropharmacol. 2015; 13(1): 47-70.10.2174/1570159X13666141210215423
10.1016/j.ajem.2009.11.008 35. Zvosec DL, Smith SW, Porrata T, Strobl AQ, Dyer JE. Case series of 226 γ-hydroxybutyrate-associated deaths: lethal toxicity and trauma. Am J Emerg Med. 2011; 29(3): 319-332.10.1016/j.ajem.2009.11.00820825811
10.1054/jcfm.2001.0473 36. Jones C. Suspicious death related to gamma-hydroxybutyrate (GHB) toxicity. Forensic and Legal Medicine 2001; 8(2): 74-76.10.1054/jcfm.2001.047315274975
10.1016/j.genhosppsych.2008.11.001 37. Noorden MS, Dongen LC, Zitman FG, Vergouwen TA. Gamma-hydroxybutyrate withdrawal syndrome: dangerous but not well-known. Gen Hosp Psychiatry. 2009; 31(4): 384-396.10.1016/j.genhosppsych.2008.11.00119555805
10.1111/j.1360-0443.1997.tb03640.x 38. Galloway GP, Frederick SL, Staggers FE Jr, Gonzales M, Stalcup SA, Smith DE. Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence. Addiction. 1997; 92(1): 89-96.10.1111/j.1360-0443.1997.tb03640.x
10.1007/s12028-008-9062-2 39. LeTourneau JL, Hagg DS, Smith SM. Baclofen and gamma-hydroxybutyrate withdrawal. Neurocrit Care. 2008; 8(3): 430-433.10.1007/s12028-008-9062-2263038818266111
10.1093/sleep/13.6.479 40. Scrima L, Hartman PG, Johnson FH Jr, Thomas EE, Hiller FC. The effects of gamma-hydroxybutyrate on the sleep of narcolepsy patients: a double-blind study. Sleep. 1990; 13(6): 479-490.10.1093/sleep/13.6.4792281247
10.1172/JCI119587 41. Cauter E, Plat L, Scharf MB, Leproult R, Cespedes S, L’Hermite-Balériaux M, et al. Simultaneous stimulation of slow-wave sleep and growth hormone secretion by gamma-hydroxybutyrate in normal young Men. J Clin Invest. 1997; 100(3): 745-753.10.1172/JCI1195875082449239423
10.1093/sleep/33.10.1295 42. Burgess CR, Tse G, Gillis L, Peever JH. Dopaminergic Regulation of Sleep and Cataplexy in a Murine Model of Narcolepsy. Sleep 2010; 33(10): 1295-1304.10.1093/sleep/33.10.1295294141521061851
43. European Medicines Agency. Xyrem: EPAR - Product Information. 2018.
10.1177/0269881108094620 44. Caputo F, Francini S, Stoppo M, Lorenzini F, Vignoli T, Del Re A, et al. Incidence of craving for and abuse of gamma-hydroxybutyric acid (GHB) in different populations of treated alcoholics: an open comparative study. Journal of Psychopharmacology 2008; 23(8): 883-890.10.1177/026988110809462018635689
45. Laboratorio Farmaceutico C.T. S.r.l. Alcover (sodium oxybate; 4-hydroxybutyric acid sodium salt): Italian summary of product characteristics. 2007.
46. G.L. Pharma GmbH. Alcover (sodium gamma hydroxybutyric acid): Austrian summary of product characteristics. 2012.
10.1093/alcalc/37.1.67 47. Nimmerrichter AA, Walter H, Gutierrez-Lobos KE, Lesch OM. Doubleblind controlled trial of c-hydroxybutyrate and clomethiazole in the treatment of alcohol withdrawal. Alcohol Alcohol. 2002; 37(1):67-73.10.1093/alcalc/37.1.6711825860
10.1097/00000374-199910000-00005 48. Addolorato G, Balducci G, Capristo E, Attilia ML, Taggi F, Gasbarrini G, et al. Gamma-hydroxybutyric acid (GHB) in the treatment of alcohol withdrawal syndrome: a randomized comparative study versus benzodiazepine. Alcohol Clin Exp Res. 1999; 23(10):1596-160410.1097/00000374-199910000-00005
10.1080/00952990701315046 49. Nava F, Premi S, Manzato E, Campagnola W, Lucchini A, Gessa GL. Gamma-hydroxybutyrate reduces both withdrawal syndrome and hypercortisolism in Sodium Oxybate: A Review 79 severe abstinent alcoholics: an open study vs. diazepam. Am J Drug Alcohol Abuse. 2007; 33(3):379-392.10.1080/00952990701315046
10.1177/0269881111408463 50. Chick J, Nutt DJ. Substitution therapy for alcoholism: time for a reappraisal? J Psychopharmacol (Oxf). 2012; 26(2):205-212.10.1177/0269881111408463
10.1016/S0741-8329(99)00085-3 51. Beghe` F, Carpanini MT. Safety and tolerability of gamma-hydroxybutyric acid in the treatment of alcohol-dependent patients. Alcohol. 2000; 20(3):223-225.10.1016/S0741-8329(99)00085-3
10.1016/j.phrs.2008.03.001 52. Stella L, Addolorato G, Rinaldi B, Capuano A, Berrino L, Rossi F, et al. An open randomized study of the treatment of escitalopram alone and combined with γ-hydroxybutyric acid and naltrexone in alcoholic patients. Pharmacol Res. 2008; 57(4):312-317.10.1016/j.phrs.2008.03.00118434189
10.1542/peds.99.4.567 53. Gibson KM, Christensen E, Jakobs C, Fowler B, Clarke MA, Hammersen G, et al. The Clinical Phenotype of Succinic Semialdehyde Dehydrogenase Deficiency (4-Hydroxybutyric Aciduria): Case Reports of 23 New Patients. Pediatrics 1997; 99(4): 567-574.10.1542/peds.99.4.5679093300
10.1002/ana.10629 54. Pearl PL, Novotny EJ, Acosta MT, Jakobs C, Gibson KM. Succinic Semialdehyde Dehydrogenase Deficiency in Children and Adults. Annals of Neurology 2003; 54(6): 73-80.10.1002/ana.1062912891657
10.1212/01.WNL.0000059549.70717.80 55. Pearl PL, Gibson KM, Acosta MT, Vezina LG, Theodore WH, Rogawski MA, et al. Clinical spectrum of succinic semialdehyde dehydrogenase deficiency. Neurology 2003; 60(9): 1413-1417.10.1212/01.WNL.0000059549.70717.8012743223
10.1111/j.1469-8749.2004.tb01015.x 56. Philippe A, Deron J, Geneviève D, de Lonlay P, Gibson KM, Rabier D, et al. Neurodevelopmental pattern of succinic semialdehyde dehydrogenase deficiency (γ-hydroxybutyric aciduria). Developmental Medicine & Child Neurology 2004; 46: 564-568.10.1111/j.1469-8749.2004.tb01015.x
10.1089/cap.2012.0130 57. Chien J, Ostermann G, Beckwitt Turkel S. Sodium Oxybate-Induced Psychosis and Suicide Attempt in an 18-Year-Old Girl. Journal of Child and Adolescent Psychopharmacology 2013; 23(4): 300-301.10.1089/cap.2012.013023647134
10.1016/j.yebeh.2011.03.009 58. Cagnin A, Pompanin S, Manfioli V, Briani C, Zambon A, Saladini M, et al. γ-Hydroxybutyric acid-induced psychosis and seizures. Epilepsy & Behavior 2011; 21(2): 203-205.10.1016/j.yebeh.2011.03.00921530412
10.3109/00952999709016901 59. Sanguineti VR, Angelo A, Frank MR. GHB: A Home Brew. Am. J. Drug Alcohol Abuse 1997; 23(4): 637-642.10.3109/00952999709016901
10.1016/j.psym.2017.10.001 60. Buckley PJ, Wolf CT. Psychosis in a 22-Year-Old Woman with Narcolepsy after Restarting Sodium Oxybate. Psychosomatics 2018; 59(3): 298-301.10.1016/j.psym.2017.10.001
10.3389/fneur.2014.00136 61. Sarkanen T, Niemelä V, Landtblom A-M, Partinen M. Psychosis in Patients with Narcolepsy as an Adverse Effect of Sodium. Frontiers in Neurology 2014; 5(136): 1-5.10.3389/fneur.2014.00136
10.4076/1757-1626-2-7520 62. Constantinides P, Vincent P. Chronic gamma-hydroxybutyric-acid use followed by gamma-hydroxybutyric-acid withdrawal mimic schizophrenia: a case report. Cases Journal 2009; 2(1): 7520.10.4076/1757-1626-2-7520
10.1520/JFS2004133 63. Pretty IA, Hall RC. Self-extraction of teeth involving gammahydroxybutyric acid. J Forensic Sci 2004; 49:1069-1072.
64. Claussen MC, Hassanpour K, Jenewein J, Boettger S. Catatonic stupor secondary to gamma-hydroxy-acid (GHB) dependence and withdrawal syndrome. Psychiatria Danubina, 2014; 26(4): 358-359.
10.1002/ana.10696 65. Wong CG, Bottiglieri T, Snead OC 3rd. GABA, gamma-hydroxybutyric acid, and neurological disease. Ann Neurol. 2003; 54 (suppl 6): 3-12.10.1002/ana.10696
10.1016/j.brainres.2006.02.131 66. Buzzi A, Wu Y, Frantseva MV, Perez Velazquez JL, Cortez MA, Liu CC, et al.Succinic semialdehyde dehydrogenase deficiency: GABAB receptor-mediated function. Brain Res. 2006; 1090: 15-22.10.1016/j.brainres.2006.02.131
10.1016/S0074-7742(06)78003-5 67. Javitt, DC. Glutamate and Schizophrenia: Phencyclidine, NMethyl-d-Aspartate Receptors, and Dopamine-Glutamate Interactions. Integrating the Neurobiology of Schizophrenia 2007; 69-108.10.1016/S0074-7742(06)78003-5
68. Testa A, Giannuzzi R, Sollazzo F, Petrongolo L, Bernardini L, Daini S. Psychiatric emergencies (part II): psychiatric disorders coexisting with organic diseases. European Review for Medical and Pharmacological Sciences 2013: 17(1): 65-85.
10.1016/0165-1781(83)90082-3 69. Levy MI, Davis BM, Mohs RC, Mathé AA, Davis KL, Trigos GC. Gamma-Hydroxybutyrate in the Treatment of Schizophrenia. Psychiatry Research 1983; 1: 1-8.10.1016/0165-1781(83)90082-3
10.1055/s-2007-1019583 70. Schutz SCh, van Kammen DP, Buchsbaum MS, Roth RH, Alexander P, Bunney jr. WE. Gamma-Hydroxybutyrate Treatment of Schizophrenia: A Pilot Study. Pharmacopsychiat. 1981; 14: 129-134.10.1055/s-2007-10195837280012
10.1111/j.1440-1819.1966.tb00055.x 71. Tanaka Z, Mukai A, Takayanagi Y, Muto A, Mikami Y, Miyakoshi T, et al. Clinical application of 4-hydroxybutyrate sodium and 4-butyrolactone in neuropsychiatric patients. Folia Psychiatr Neurol Jpn. 1966; 20(1): 9-17.10.1111/j.1440-1819.1966.tb00055.x5340823
10.1016/0014-2999(94)90248-8 72. Maitre M, Ratomponirina C, Gobaille S, Hodé Y, Hechler V. Displacement of [3H] gamma-hydroxybutyrate binding by benzamide neuroleptics and prochlorperazine but not by other antipsychotics. Eur J Pharmacol. 1994; 256(2): 211-214.10.1016/0014-2999(94)90248-8
10.1016/0014-2999(91)90896-X 73. Schmidt C, Gobaille S, Hechler V, Schmitt M, Bourguignon JJ, Maitre M. Anti-sedative and anti-cataleptic properties of NCS-382, a γ-hydroxybutyrate receptor antagonist. Eur. J. Pharmacol. 1991; 203(3): 393-397.
74. Rzewuska M. Amisulprid w leczeniu chorych na schizofrenię - podsumowanie danych, 2008. Farmakoterapia w Psychiatrii i Neurologii 2008; 4: 227-242.
75. Sulpiryd Teva. Charakterystyka produktu leczniczego. leki.urpl.gov.pl 2012. [dostęp 2018-08-29].
76. Rzewuska M. Amisulpryd - atypowy lek przeciwpsychotyczny drugiej generacji. Farmakoterapia w Psychiatrii i Neurologii 2001; 3: 257-284.
10.1016/S0140-6736(13)60733-3 77. Leucht S, Cipriani A, Spineli L, Mavridis D, Örey D., Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. The Lancet 2013; 382(9896): 951-962.10.1016/S0140-6736(13)60733-3
78. Jarema M, Meder J, Araszkiewicz A, Tyszkowska M. Leki przeciwpsychotyczne w praktyce lekarza psychiatry. Leczenie pierwszwego epizodu schizofrenii. Psychiatria Polska 2008;
79. Stahl SM. Podstawy psychofarmakologii. Teoria i praktyka. T. 2. Gdańsk: Via Medica, 2009, s. 179-183. ISBN 978-83-7599-070-6.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.